Acheter Lucius Pralsetinib en ligne

EUR 502.67

2,900+ vendus
Prix promo

Pharmacie physique à Hong Kong, authenticité 100% garantie

Points forts

2020 9 FDA , RET KIF5B-RET CCDC6-RET RET V804L/M M918T ,

Garanties de service

Expédition transfrontalièrePharmacie agrééeContrôle pharmacienGarantie authenticité

Caractéristiques

Spécification
100mg*120 gelules
Fabricant
Lucius Pharmaceuticals
Expédition
Hong Kong

10000 en stock

Catégorie : Étiquettes : , , Marque :

Informations produit

Nom anglais
Pralsetinib
Nom générique
Pralsetinib

Caractéristiques

Spécification
100mg*120 gelules
Fabricant
Lucius Pharmaceuticals
Expédition
Hong Kong

Détails complets

Mécanisme d’action

, RET RET CCDC6-RET RET V804L RET V804M RET M918T , IC50 0.5 nM , , DDR1 TRKC FLT3 JAK1-2 TRKA VEGFR2 PDGFRB FGFR1 , RET VEGFR2 FGFR2 JAK2 14 40 12 RET ,

Pharmacologie

12.1 Mecanisme d action , RET RET CCDC6-RET RET V804L RET V804M RET M918T , IC50 0.5 nM , Cmax , DDR1 TRKC FLT3 JAK1-2 TRKA VEGFR2 PDGFRB FGFR1 , RET VEGFR2 FGFR2 JAK2 14 40 12 RET

Posologie

2.1 RET GAVRETO [ (14)] FDA RET , GAVRETO 400 mg, GAVRETO 2 1 [ (12.3)]

Precautions

5.1 / GAVRETO (ILD) / GAVRETO ,12% , 3.3% 3-4 ,0.2% ILD / , GAVRETO ILD ILD , GAVRETO [ Posologie (2.3)]

Interactions médicamenteuses

7.1 GAVRETO CYP3A / P-gp CYP3A / P-gp [ (12.3)], GAVRETO GAVRETO CYP3A / P-gp , GAVRETO [ Posologie (2.4)] CYP3A CYP3A [ (12.3)], GAVRETO

Effets indésirables

Description / [ Precautions(5.1)] [ Precautions(5.2)] [ Precautions(5.3)] [ Precautions(5.4)] [ Precautions(5.5)] [ Precautions(5.6)] - [ Precautions(5.7)] 6.1 ,

Conservation

GAVRETO 100 , , , , HPMC , “BLU-667”, “100 ”, 60 NDC 50242-210-60 90 NDC 50242-210-90 120 NDC 50242-210-12

Package Insert

Posologie

2.1 RET GAVRETO [ (14)] FDA RET , GAVRETO 400 mg, GAVRETO 2 1 [ (12.3)]

Effets indésirables

Description / [ Precautions(5.1)] [ Precautions(5.2)] [ Precautions(5.3)] [ Precautions(5.4)] [ Precautions(5.5)] [ Precautions(5.6)] - [ Precautions(5.7)] 6.1 ,

Precautions

5.1 / GAVRETO (ILD) / GAVRETO ,12% , 3.3% 3-4 ,0.2% ILD / , GAVRETO ILD ILD , GAVRETO [ Posologie (2.3)]

Use in Pregnancy and Lactation

8.1 Mecanisme d action,GAVRETO [ (12.1)] GAVRETO , , , , 400 mg ,

Interactions médicamenteuses

7.1 GAVRETO CYP3A / P-gp CYP3A / P-gp [ (12.3)], GAVRETO GAVRETO CYP3A / P-gp , GAVRETO [ Posologie (2.4)] CYP3A CYP3A [ (12.3)], GAVRETO

Clinical Pharmacology

12.1 Mecanisme d action , RET RET CCDC6-RET RET V804L RET V804M RET M918T , IC50 0.5 nM , Cmax , DDR1 TRKC FLT3 JAK1-2 TRKA VEGFR2 PDGFRB FGFR1 , RET VEGFR2 FGFR2 JAK2 14 40 12 RET ,

Clinical Studies

14.1 RET ARROW,NCT03037385 , GAVRETO RET NSCLC RET NSCLC , NSCLC RET NGS FISH , 237 , 40%

Conservation

GAVRETO 100 , , , , HPMC , “BLU-667”, “100 ”, 60 NDC 50242-210-60 90 NDC 50242-210-90 120 NDC 50242-210-12

Avis produit (17)

Filtre : Tous les avis
4.8★★★★★
17 avis clients14 achats verifies
+o***e· il y a 3 semaines
★★★★
+t***3· il y a 1 mois
Achat verifie
★★★★★

Description

Mécanisme d’action

, RET RET CCDC6-RET RET V804L RET V804M RET M918T , IC50 0.5 nM , , DDR1 TRKC FLT3 JAK1-2 TRKA VEGFR2 PDGFRB FGFR1 , RET VEGFR2 FGFR2 JAK2 14 40 12 RET ,

Pharmacologie

12.1 Mecanisme d action , RET RET CCDC6-RET RET V804L RET V804M RET M918T , IC50 0.5 nM , Cmax , DDR1 TRKC FLT3 JAK1-2 TRKA VEGFR2 PDGFRB FGFR1 , RET VEGFR2 FGFR2 JAK2 14 40 12 RET

Posologie

2.1 RET GAVRETO [ (14)] FDA RET , GAVRETO 400 mg, GAVRETO 2 1 [ (12.3)]

Precautions

5.1 / GAVRETO (ILD) / GAVRETO ,12% , 3.3% 3-4 ,0.2% ILD / , GAVRETO ILD ILD , GAVRETO [ Posologie (2.3)]

Interactions médicamenteuses

7.1 GAVRETO CYP3A / P-gp CYP3A / P-gp [ (12.3)], GAVRETO GAVRETO CYP3A / P-gp , GAVRETO [ Posologie (2.4)] CYP3A CYP3A [ (12.3)], GAVRETO

Effets indésirables

Description / [ Precautions(5.1)] [ Precautions(5.2)] [ Precautions(5.3)] [ Precautions(5.4)] [ Precautions(5.5)] [ Precautions(5.6)] - [ Precautions(5.7)] 6.1 ,

Conservation

GAVRETO 100 , , , , HPMC , “BLU-667”, “100 ”, 60 NDC 50242-210-60 90 NDC 50242-210-90 120 NDC 50242-210-12